<DOC>
	<DOCNO>NCT00451048</DOCNO>
	<brief_summary>This phase II trial study well sunitinib work treat patient myelodysplastic syndrome chronic myelomonocytic leukemia . Sunitinib may stop growth abnormal cell block enzymes need cell growth .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall response rate ( complete response , partial response , hematological improvement ) patient intermediate-2 high-risk myelodysplastic syndrome chronic myelomonocytic leukemia treat sunitinib malate . II . Determine duration response patient treated drug . III . Determine overall survival patient treated drug . IV . Determine progression-free survival patient treated drug . V. Determine time disease progression patient treat drug . VI . Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3-4 week monthly thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>MDS syndromes meet 1 following : Intermediate2 disease , highrisk disease ( IPSS score &gt; =1.5 ) CMML : WBC &gt; 12,000/mm^3 , Intermediate2 disease WBC= &lt; 12,000/mm^3 , highrisk disease ( IPSS score &gt; =1.5 ) WBC= &lt; 12,000/mm^3 Patients insufficient/inadequate metaphase cytogenetic analysis eligible bone marrow blast &gt; 10 % and/or 23 cytopenias present No known brain metastasis Life expectancy &gt; 12 week ECOG PS 02/Karnofsky PS 60100 % Calcium= &lt; 3.0 mmol/L Bilirubin normal AST ALT= &lt; 2.5 time upper limit normal Creatinine normal/creatinine clearance &gt; =60 mL/min No history significant ECG abnormality include limited : ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation &gt; =3 beat row ) ; QTc prolongation ( i.e.QTc interval &gt; =500msec ) No history allergic reaction compound similar chemical/biological composition sunitinib malate No NYHA class IIIIV congestive heart failure Patients history NYHA class II congestive heart failure asymptomatic treatment eligible No abdominal fistula/G perforation/intraabdominal abscess within past 28 day No serious cardiovascular disease within past 12 month include : cerebrovascular accident transient ischemic attack , myocardial infarction , cardiac arrhythmia , stable unstable angina , symptomatic congestive heart failure , coronary peripheral artery bypass graft stenting No pulmonary embolism within past 12 month No uncontrolled hypertension ( systolic BP &gt; =140 mmHg/diastolic BP &gt; =90 mmHg ) No condition impair ability swallow/retain sunitinib malate tablet include : GI tract disease result inability take oral medication , requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease No serious/nonhealing wound , ulcer , bone fracture No uncontrolled preexist thyroid abnormality No concurrent uncontrolled illness include ongoing/active infection No psychiatric illness/social situation would preclude study participation Not pregnant/nursing Negative pregnancy test Fertile patient must use effective barrier contraception 4 week since prior major surgery Prior central thoracic radiotherapy include heart radiotherapy port allow provide NYHA congestive heart failure= &lt; class II Prior anthracycline exposure allow provide NYHA congestive heart failure= &lt; class II No prior therapy MDS/CMML except epoetin alfa , darbepoetin alfa , filgrastim sargramostim At least 2 week since prior epoetin alfa At least 4 week since prior darbepoetin alfa No prior antiangiogenic agent include limited : bevacizumab , sorafenib tosylate , pazopanib hydrochloride , AZD2171 , vatalanib , VEGF Trap More 7 day since prior concurrent potent CYP3A4 inhibitor More 12 day since prior concurrent potent CYP3A4 inducer include : Rifampin , Rifabutin , Carbamazepine , Phenobarbital , Phenytoin , Hypericum perforatum , Efavirenz , Tipranavir No concurrent birth control patch/oral birth control pills/depot/injectable birth control methods No concurrent therapeutic coumarinderivative anticoagulant Low dose ( = &lt; 2mg ) warfarin prophylaxis thrombosis allow Low molecular weight heparin allow INR= &lt; 1.5 No concurrent agent proarrhythmic potential include : Terfenadine , Quinidine , Procainamide , Disopyramide , Sotalol , Probucol , Bepridil , Haloperidol , Risperidone , Indapamide , Flecainide acetate No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>